BTK-IN-49 is a selective, orally active and brain-penetrant BTK inhibitor with an IC50 of 0.14 nM. BTK-IN-49 binds to BTK and blocks B-cell receptor and Fcgamma receptor signaling. BTK-IN-49 inhibits the proliferation of CNS-compartmentalized B-cells and FcgammaR-induced microglial proliferation in a BTK-dependent manner. BTK-IN-49 can be used for the study of multiple sclerosis[1].
Molecular Weight:
486.57
Formula:
C26H30N8O2
Target:
Btk,Fc Receptor (FcR)
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
